Y-mAbs Therapeutics falls following gloomy 2025 revenue forecast

Y-mAbs Therapeutics

04/03/2025 16:23

** Shares of drugmaker Y-mAbs Therapeutics YMAB.O fall 8.5% to $4.75, hitting a near two-year low

** Company forecasts 2025 total revenue to be between $75 million and $90 million, below analysts' estimates of $104.54 million, according to data compiled by LSEG

** YMAB reports Q4 total revenue of $26.5 million, below analysts' estimates of $27.29 million

** In the past 12 months, YMAB has fallen 70%

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))